Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 15/20 | 0.77 |
| ▸ | GABRB3 | P28472 | 15/20 | 0.77 |
| ▸ | GABRA3 | P34903 | 12/20 | 0.77 |
| ▸ | GABRA5 | P31644 | 12/20 | 0.77 |
| ▸ | GABRA2 | P47869 | 10/20 | 0.77 |
| ▸ | GABRA1 | P14867 | 8/20 | 0.77 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.77 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.77 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16638525 | 0.91 | GABRG2 (0.74) | GABRG2GABRB3GABRA3GABRA5GABRA2 | |
| SCHEMBL639410 | 0.90 | GABRG2 (0.71) | GABRG2GABRB3GABRA3GABRA5GABRA2 | |
| SCHEMBL10045479 | 0.89 | GABRG2 (0.77) | GABRG2GABRB3GABRA3GABRA5GABRA2 | |
| SCHEMBL637699 | 0.88 | GABRG2 (0.79) | GABRG2GABRB3GABRA3GABRA5GABRA2 | |
| SCHEMBL638718 | 0.87 | GABRG2 (1.00) | GABRG2GABRB3GABRA3GABRA5GABRA2 | |
| SCHEMBL637991 | 0.87 | GABRA3 (0.74) | GABRG2GABRB3GABRA3GABRA5GABRA2 | |
| SCHEMBL639291 | 0.87 | GABRG2 (0.74) | GABRG2GABRB3GABRA3GABRA5GABRA2 | |
| Hydrochloric Acid SCHEMBL638037 | 0.86 | GABRG2 (0.74) | GABRG2GABRB3GABRA3GABRA5GABRA2 | |
| Hydrochloric Acid SCHEMBL4081656 | 0.86 | GABRG2 (0.74) | GABRG2GABRB3GABRA3GABRA5GABRA2 | |
| SCHEMBL13835287 | 0.86 | GABRA3 (0.73) | GABRG2GABRB3GABRA3GABRA5GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093466-A1 | Carboxamide GABAa ALPHA2 Modulators | BRISTOL-MYERS SQUIBB COMPANY | 2009-04-09 | — | — | US | claimed |
| US-8119629-B2 | Carboxamide GABAA α2 modulators | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2012-02-21 | — | — | US | disclosed |
| US-20090093466-A1 | Carboxamide GABAa ALPHA2 Modulators | BRISTOL-MYERS SQUIBB COMPANY | 2009-04-09 | — | — | US | disclosed |
| WO-2009046004-A1 | CARBOXAMIDE GABAA ALPHA2 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093466-A1 | Carboxamide GABAa ALPHA2 Modulators | GABRA2, GABRB2, GABRB1 | GABRG2 12/4885GABRB3 7/4885GABRA3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.